Specimen Collection HEMATOLOGICAL MALIGNANCIES. CGI LABORATORIES 201 Route 17 North, 2nd Floor Rutherford, NJ SOLID TUMORS
|
|
- Jesse Robinson
- 7 years ago
- Views:
Transcription
1 Specimen Collection Specimen Retrieval Kits 2 Sending your Specimens 2 Labeling Instructions 2 Handling of a Bone Marrow Specimen Dry Tap 3 CGI LABORATORIES 201 Route 17 North, 2nd Floor Rutherford, NJ Client Services: Tel: Toll Free: Fax: specimen@cgix.com HEMATOLOGICAL MALIGNANCIES Anaplastic Large Cell Lymphoma (ALCL) 4 Acute Lymphocytic Leukemia (ALL) 4 Acute Myeloid Leukemia (AML) 4 Burkitt Lymphoma 4 Chronic Lymphocytic Leukemia (CLL) 5 Chronic Myelogenous Leukemia (CML) 5 Diffuse Large B-Cell Lymphoma (DLBCL) 6 follicular lymphoma (FL) 6 Lymphoma 7 MALT Lymphoma 7 Mantle Cell Lymphoma (MCL) 7 Myelodysplastic Syndrome (MDS) 8 Multiple Myeloma (MM) 8 Myeloproliferative Neoplasms (MPN) 8 Paroxysmal Nocturnal Hemoglobinuria (PNH) 9 SOLID TUMORS Bladder 9 Breast 9 Cervical 9 Colorectal (CRC) 9 Kidney 10 Melanoma 10 Non-Small Cell Lung Cancer (NSCLC) 10 Thyroid 10
2 Specimen Collection Specimen Retrieval Kits Supplies and containers for our laboratory services are permitted by State and Federal laws. CGI will provide you, at no charge, with all the supplies you need: requisition forms, tubes, packaging transport forms, etc. Supply requests can be submitted to us by contacting your account manager or by contacting our accessioning department. You can reach the department by phone at (888) or by Sending Your Specimens When you first sign up with CGI, your account representative will help you determine your specific courier needs, which are decided according to your geographical location. Our service runs both day and night, based upon our clients schedules, to ensure that our clients are able to continue to operate according to their own established schedule. FedEx is available for all clients outside of our local geographic region. Regardless of the method used, CGI will provide prompt and efficient service to ensure that clients receive results in a timely manner. Our accessioning office can be reached by phone (888) , or by specimen@cancergenetics.com. Labeling Instructions Based on regulatory requirements, all specimen containers must be labeled with at least two patient identifiers such as, patient name and date of birth. Also, the collection dates and times must be on either the requisition or specimen container. All specimens received in the laboratory must have a completed requisition form with all appropriate information filled out, including: Patient name Patient DOB Collection data/time Specimen type/site Requesting physician 2
3 Bone Marrow Dry Tap Handling of a Bone Marrow Specimen Dry Tap CGI has a very high success rate with limited amounts of marrow as well as with more cellular aspirate specimens. The following specimen collection method can help our hemato-pathologists to reach a conclusive diagnosis on these types of specimens: 1. Collect 2 or more bone marrow core biopsies a. Make 5-10 touch imprint slides from the biopsies (for Cytology and ) Be sure to keep slides AWAY FROM FORMALIN Do not place open formalin jar anywhere near slides as the formalin fumes may affect the quality of morphologic evaluation Let all slides AIR DRY COMPLETELY before placing in the plastic container to prevent smudging b. Place the 1st bone marrow core biopsy in a Formalin jar (for Histology & IHC testing) c. Place the 2nd biopsy in RPMI media (for Flow Cytometry and/or Cytogenetics testing) Store in refrigerator until shipped d. Additional samples/clot should be submitted for histology 2. Indicate on REQUISITION that the specimen is a DRY TAP 3. Collect a peripheral blood specimen in a Sodium Heparin or green top tube (for possible Flow Cytometry and/or FISH testing, if indicated) 4. Collect a peripheral blood specimen in an EDTA or purple top tube (for possible molecular testing, if indicated) 5. Place each specimen in the Biohazard bag before placing in kit 6. Call or for a specimen pickup or contact your local account representative or client services if you have any questions. 3
4 Hematological Malignancies (ALCL - Burkitt Lymphoma) ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) ALCL FISH Panel ACUTE LYMPHOCYTIC LEUKEMIA (ALL) Myeloid/Lymphoid/Acute Leukemia Panel (Flow) B-ALL FISH Panel T-ALL FISH Panel ACUTE MYELOID LEUKEMIA (AML) Myeloid/Lymphoid/Acute Leukemia Panel (Flow) AML FISH Panel c-kit Mutation (Exon 8 & 17) CEBPA Mutation FLT3 Mutation NPM1 Mutation 2-8 C. BURKITT LYMPHOMA MYC/IGH DNA-FISH Probe 4
5 Hematological Malignancies (CLL, CML) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ZAP-70 Panel (Flow) CLL FISH Panel IGHV Mutation NOTCH1 Mutation SF3B1 Mutation TP53 Mutation MatBA -CLL/SLL CLL Complete 2-8 C. Peripheral Blood or Bone Marrow Aspirate: 1 lavender/edta tube with minimum 2-3 ml at FFPE: 3-5 FFPE sections at 10 μm thickness on regular slides at Peripheral Blood or Bone Marrow Aspirate: 1 lavender/edta tube with minimum 5-7 ml at FFPE: FFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on ice. CHRONIC MYELOGENOUS LEUKEMIA (CML) Myeloid/Lymphoid/Acute Leukemia Panel (Flow) CML FISH Panel CML in Blast Crisis FISH Panel ABL Kinase Domain Mutation BCR/ABL Qualitative BCR/ABL Quantitative Major & Minor 1 Lavender/EDTA tube peripheral blood or bone marrow (3-5 ml) at room temperature or 2-8 C within 48 hours after collection. 5
6 Hematological Malignancies (Lymphoma) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) cmyc, Ki-67 (IHC) GCB vs. Non-GCB Subtyping (IHC) Lymphoid Panel (Flow) NHL FISH Panel B-Cell Clonality (IGH) TP53 Mutation MatBA -DLBCL DLBCL Complete SM 2-8 C or μm total FFPE sections at 2-8 C. FFPE: block containing 70% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at Fresh-Frozen Tissue: 0.2 cm3 minimum (in OCT is acceptable) containing 50% tumor. Stored at -80 C /-20 C, shipped on dry ice. Peripheral Blood or Bone Marrow Aspirate: 1 lavender/edta tube with minimum 5-7 ml at FFPE: FFPE tissue block at room temperature or 0.5 cm 3 fresh tissue in RPMI on ice. FOLLICULAR LYMPHOMA (FL) Lymphoid Panel (Flow) NHL FISH Panel MatBA -FL FFPE: block containing 70% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at Fresh-Frozen Tissue: 0.2 cm 3 minimum (in OCT is acceptable) containing 50% tumor. Stored at -80 C /-20 C, shipped on dry ice. 6
7 Hematological Malignancies (Lymphoma Continued) LYMPHOMA Lymphoid Panel (Flow) NHL FISH Panel B-Cell Clonality (IGH) T-Cell Clonality (TCRβ) T-Cell Clonality (TCRγ) MYD88 Mutation 2-8 C or μm total FFPE sections at 2-3 ml peripheral blood or bone marrow in an EDTA tube (Lavender-top). Specimen should be stored, transported at room temperature or 2-8 C. MALT LYMPHOMA Lymphoid Panel (Flow) NHL FISH Panel MANTLE CELL LYMPHOMA (MCL) Lymphoid Panel (Flow) NHL FISH Panel MatBA -MCL Peripheral Blood: minimum 3-5 ml, shipped at FFPE: block containing 60% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at Fresh-Frozen Tissue: 0.2 cm 3 minimum (in OCT is acceptable) containing 50% tumor. Stored at -80 C /-20 C, shipped on dry ice. 7
8 Hematological Malignancies (MDS, MM, MPN) MYELODYSPLASTIC SYNDROME (MDS) MDS FISH Panel MULTIPLE MYELOMA (MM) MM Panel (Flow) MM with PPC FISH Panel MYELOPROLIFERATIVE NEOPLASMS (MPN) Myeloid/Lymphoid/Acute Leukemia Panel (Flow) MPN FISH Panel ABL Kinase Domain Mutation BCR/ABL Quantitative Major & Minor CALR Mutation c-kit Mutation (D816) JAK2 Exon 12 Mutation JAK2 V617F Mutation MPL 515/505 Mutation MPN Complete SM 1 Lavender/EDTA tube peripheral blood or bone marrow (3-5 ml) at room temperature or 2-8 C within 48 hours after collection. 2-8 C. Peripheral Blood or Bone Marrow Aspirate: 1 lavender/edta tube with minimum 5-7 ml at room temperature or 2-8 C. FFPE: FFPE tissue block at 8
9 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PNH Test (Flow) Solid Tumors (Bladder, Breast, Cervical, Colorectal) BLADDER CANCER UroVysion ml urine in a suitable container. Same day shipping or PreservCyt should be used if the specimen will remain in transit for more than a day to ensure stability. BREAST CANCER PathVysion 3-5 µm thick FFPE sections on positively coated slides at Breast Complete SM CERVICAL CANCER FHACT Liquid cytology in PreservCyt or SurePath. Specimens should be sent within 3 weeks after collection. Specimens may be shipped at room temperature ( 25 C) but shipping at 4 C is recommended. Specimens shall not be frozen. Specimen volume recommended >10 ml. COLORECTAL CANCER (CRC) MMR Profile BRAF Mutation KRAS Mutation NRAS Mutation Micro-Satellite Instability PIK3CA Mutation CRC Complete SM FFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides. Should contain both normal and tumor tissues from the same patient. Specimen contains over 20% of tumor cells FFPE tissue block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides and 4-5 μm thick FFPE sections on positively coated slides at 9
10 Solid Tumors (Kidney, Melanoma, NSCLC, Thyroid) KIDNEY CANCER UroGenRA -Kidney Biopsy: minimum 3-4 needle/core biopsies (18-gauge needle) placed in a cryovial containing saline, transport frozen. (Minimum 70% tumor population). Resected Specimen: minimum of 0.2 cm 3 tissue, snap-frozen in a cryovial and transported in frozen condition. (Minimum 70% tumor population). MELANOMA BRAF Mutation BRAF cobas Mutation NRAS Mutation FFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides. NON-SMALL CELL LUNG CANCER (NSCLC) ALK Break Apart DNA- FISH Probe ROS1 DNA-FISH Probe EGFR Mutation EGFR cobas Mutation KRAS Mutation Lung Complete SM 5 FFPE sections at 3-5 μm thickness on positively coated slides at FFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides. FFPE tissue block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells and 5 FFPE sections at 3-5 μm thickness at THYROID CANCER BRAF Mutation NRAS Mutation FFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides. v
Cancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
More informationWHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?
WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? Which test should be submitted? The answer to this depends on the clinical signs, and the diagnostic question you are asking. If
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationHAEMATOLOGY LABORATORY
HAEMATOLOGY LABORATORY Head of Unit : Dr Raudhawati Osman Phone : +603-26155281 Email : raudhaosman@yahoo.com 1. INTRODUCTION The Haematology Unit, Department of Pathology, HKL provides tertiary diagnostic
More informationPlease note: Contact Coppe Laboratories at 262-574-0701 if archival plasma samples need to be tested.
Collecting a Coppe Laboratories Sample The Coppe Laboratories Sample Kit contains: Test Request Form (TRF) Heparin tube Absorbent sheet Biohazard bag Foil pouch Label for blood tube Box Seal Instructions
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationMarch 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,
Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationPROCUREMENT OF BONE MARROW SPECIMENS
Page 1 of 8 SITES AFFECTED _X Enterprise Chandler Good Samaritan PROCUREMENT OF BONE MARROW SPECIMENS A technologist at Chandler CORE and Samaritan are assigned to Bone Marrow duties Monday through Friday
More informationReference Range: 0.5-1.6 mmol/l (arterial) 0.7-2.1 mmol/l (venous) CPT Code: 83605
LACTIC ACID Fasting, arterial specimen preferred. Please note whether arterial or venous. 0.5 ml heparinized plasma. Green top or PST must be drawn, placed on ice, and spun within 15 minutes. Immediately
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationSEER SINQ s. Finalized March 2011
ized March 2011 : 20110067 First course treatment--heme & Lymphoid Neoplasms: Are the treatment guidelines in the "red book" still valid? See discussion. While I realize that the Hematopoietic Database
More informationCANCER GENETICS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended
More informationClinical Information Systems to Support Personalized Medicine at the Bedside
Clinical Information Systems to Support Personalized Medicine at the Bedside March 2012 Mia Levy, MD, PhD Director Cancer Clinical Informatics, Vanderbilt Ingram Cancer Center Assistant Professor of Biomedical
More informationInteresting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
More informationMolecular Stratification of Cancer in the
Molecular Stratification of Cancer in the Clinical Setting David Gonzalez de Castro Molecular Diagnostics NHS FT and The Institute of Cancer Research, London, UK 1 2 The complexity of human cancer genomes
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
More informationUpdating the 2008 WHO Classification of Small B cell lymphomas Elias Campo
Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Barcelona, Spain Disclosure of Relevant Financial Relationships Dr. ELIAS CAMPO declares
More informationAbout B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationThe Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
More informationPathology No: SHS-CASE No. Date of Procedure: Client Name Address
TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,
More informationAcute leukemias and myeloproliferative neoplasms
Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is
More informationFredrik.Enlund@gu.se Sahlgrenska universitetssjukhuset
Fredrik.Enlund@gu.se Sahlgrenska universitetssjukhuset 1 Techniques for sarcoma diagnostics Molecular Pathology of Solid Tumors Uppsala 120924 Klinisk Molekylär Patologi Klinisk Patologi och Cytologi Gene
More informationCytogenetics for the Rest of Us: A Primer
Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationCANCER GENETICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended
More informationAdvancing Therapies for Blood Cancers
Advancing Therapies for Blood Cancers Stuart L. Goldberg, MD Chief, Division of Leukemia John Theurer Cancer Center Hackensack University Medical Center Hackensack, NJ Associate Clinical Professor of Medicine
More information6/20/2014. PART I: Plasma Cell Myeloma. Plasma Cells
MULTIPLE MYELOMA: THE TESTING, VALIDATION AND IMPLEMENTATION OF CELL SEPARATION TECHNOLOGY FOR IMPROVED PATIENT CARE Elizabeth Harper CG(ASCP), Binh Vo CG(ASCP), Joey Pena CG(ASCP), Denise Lovshe CG(ASCP),
More informationBone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital
Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.
More informationGenomic Medicine Education Initiatives of the College of American Pathologists
Genomic Medicine Education Initiatives of the College of American Pathologists Debra G.B. Leonard, MD, PhD, FCAP Chair, Personalized Healthcare Committee, CAP Professor of Pathology, Weill Cornell Medical
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationOncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
More informationCollect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.
Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,
More informationDiffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition
Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone L. Jeffrey Medeiros, M.D. M.D. Anderson Cancer Center Relative Frequency of B-cell NHL Diffuse large B-cell lymphoma 37 % Follicular lymphoma
More informationCAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
More informationCollaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
More informationinformation for payers and referrers
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in
More informationImmunohistochemical classification of malignant lymphomas
Immunohistochemical classification of malignant lymphomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Thanks to Jan Klos Important issues Distinction from non-hematopoietic neoplasms
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationFlow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma
Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI,NIH DEPARTMENT OF HEALTH & HUMAN SERVICES
More informationSubtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.
1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow
More informationIMMEDIATE HOT LINE: Effective March 2, 2015
MEDICARE COVERAGE OF LABORATORY TESTING Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply: 1. Only
More informationPEAC CENTRAL LABORATORY SAMPLING MANUAL
PEAC CENTRAL LABORATORY SAMPLING MANUAL FINAL REVISED VERSION (9.0) PEAC Clinical Study Final 1.0 2 TABLE OF CONTENTS Page No. 1. PEAC CENTRAL LABORATORY - CONTACT NUMBERS... 3 2. IMPORTANT INFORMATION...
More informationLymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH
Lymphoplasmacytic Lymphoma versus IGM Multiple Myeloma Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Hematology consult patient 48 yo woman presents to ER with nonspecific complaints:
More informationMature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed
Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms Dr. Douaa Mohammed Sayed Small lymphocytic lymphoma/b-cell chronic lymphocytic leukemia BMB: nodular, interstitial, diffuse or a combination
More informationGenomic Analysis of Mature B-cell Malignancies
Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:
More informationA23: Oncologic Disease- Tumor Markers
A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of
More informationCancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN
Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing
More informationFlow Cytometric Evaluation of B-cell Lymphoid Neoplasms
Clin Lab Med 27 (2007) 487 512 Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Fiona E. Craig, MD Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine,
More informationSecond Cancers in Adults
Second Cancers in Adults This document focuses on second cancers in adults. For information about second cancers after treatment of childhood cancers, see our document Children Diagnosed With Cancer: Late
More informationAcute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
More informationFor years, drug developers have used histology as the
NOVEL Clinical Trial Designs in oncology: An Histology-Independent Approach Cancer s heterogeneity is a leading reason why product development in this therapeutic area is so risky and costly and why the
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More informationHodgkin and Non-Hodgkin Lymphoma Pre-HCT Data
(Form 2018) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form. E-mail comments regarding the content
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationNon Hodgkin Lymphoma:
Non Hodgkin Lymphoma: Non Hodgkin Lymphoma, often referred to as NHL, is a cancer originating in the lymphocytes, a type of blood cell, which are integral to the body s immune system. Non Hodgkin Lymphoma
More informationThis presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking
Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
More informationChronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More informationGuidelines for Handling and Shipping of Blood Samples
Biofocus Institute for Laboratory Medicine Dr. med. Doris Bachg Dr. med. Uwe Haselhorst Berghäuser Str. 295 45659 Recklinghausen Germany contact: Dr. Doris Bachg (bachg@biofocus.de) phone +49 2361 3000-144
More informationINTRODUCTION. Viral shedding is crucial for Gene Therapy Products Safety linked with shedding data
INTRODUCTION Viral shedding is crucial for Gene Therapy Products Safety linked with shedding data For the patient For families and friends For the environment No treatment possible without good safety
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationHematologic Malignancies
Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationLung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology
Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists
More informationValidation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach
Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Kerry C. Councilman, MD Assistant Professor University of Colorado Denver Goals: BRAF Mutation
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationMain Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup.
Main Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup.com Presented by Ted Mageau Ted@MainStreetPlanningGroup.com Life
More informationNext Generation Sequencing of Hematologic Neoplasms
Next Generation Sequencing of Hematologic Neoplasms Todd W. Kelley, M.D. Associate Professor of Pathology University of Utah Medical Director of Molecular Hematopathology ARUP Laboratories Salt Lake City,
More informationB-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2008 WHO Classification of Lymphoid Neoplasms: Small B-Cell Neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Splenic marginal zone B-cell lymphoma Hairy
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationUnderstanding Non-Hodgkin Lymphoma
Understanding Non-Hodgkin Lymphoma A Guide For Patients, Survivors, and Loved Ones Fourth Edition This guide is an educational resource compiled by the Lymphoma Research Foundation (LRF) that provides
More informationNGS e malattie mieloproliferative
NGS e malattie mieloproliferative Matteo G Della Porta Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia Medical School, Pavia, Italy matteo@haematologica.org
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationNew Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationCord blood Banking Transplant List for One USA Bank - StemCyte www.stemcyte.com/cordblood-banking-transplant-list
Cells4Life is the oldest and largest cord blood storage company in the UK. We are governed by some of the world's most stringent medical laws, and are currently the only stem cell storage company in the
More informationncounter Leukemia Fusion Gene Expression Assay Molecules That Count Product Highlights ncounter Leukemia Fusion Gene Expression Assay Overview
ncounter Leukemia Fusion Gene Expression Assay Product Highlights Simultaneous detection and quantification of 25 fusion gene isoforms and 23 additional mrnas related to leukemia Compatible with a variety
More informationApplications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session
More informationCorporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid
Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationHospital-Based Tumor Registry. Srinagarind Hospital, Khon Kaen University
Hospital-Based Tumor Registry Srinagarind Hospital, Khon Kaen University Statistical Report 2012 Cancer Unit, Faculty of Medicine Khon Kaen University Khon Kaen, Thailand Tel & Fax:+66(43)-202485 E-mail:
More informationREFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
More informationNEOPLASMS C00 D49. Presented by Jan Halloran CCS
NEOPLASMS C00 D49 Presented by Jan Halloran CCS 1 INTRODUCTION A neoplasm is a new or abnormal growth. In the ICD-10-CM classification system, neoplastic disease is classified in categories C00 through
More informationLaunching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment
Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment Arthur L. Beaudet, M.D. Department of Molecular and Human Genetics Baylor College of Medicine ORIGIN AND PRECEDENT Decades of experience
More informationUtility of flow cytometric κ and λ light chain analysis of peripheral blood
JBUON 2015; 20(5): 1322-1326 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Utility of flow cytometric κ and λ light chain analysis of peripheral
More informationPediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
More informationGeneral Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
More informationAWLP Lymphoma Course and Workshop 9-10 November 2011 Hilton, Cardiff City Centre PROGRAMME
AWLP Lymphoma Course and Workshop 9-10 November 2011 Hilton, Cardiff City Centre PROGRAMME Sponsored by This course and workshop are designed for more experienced trainees in Histopathology, Haematology
More informationCHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
More informationGebruik van predictieve markers voor targeted therapy in de algemene praktijk
Gebruik van predictieve markers voor targeted therapy in de algemene praktijk Gerrit A. Meijer, MD, PhD Professor of Pathology Chair of the Department of Pathology VU Universtiy Medical Center Amsterdam
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More information